Dormann H, Neubert A, Criegee-Rieck M, Egger T, Radespiel-Tröger M, Azaz-Livshits T, Levy M, Brune K, Hahn E G
Department of Internal Medicine I, University of Erlangen-Nuremberg, Erlangen, Germany.
J Intern Med. 2004 Jun;255(6):653-63. doi: 10.1111/j.1365-2796.2004.01326.x.
Recent studies show that nearly half of the hospitalized patients are readmitted within 6 months from discharge. No data exist about the relationship between adverse drug reactions (ADRs) and readmittance to a department of internal medicine.
The primary aims of the study were to determine if ADRs could be used as predictors for recurrent hospitalizations in internal medicine and to evaluate the economic impact of ADRs on hospitalization costs.
A cohort-based, prospective, 18-month pharmacoepidemiological survey was conducted in the Department I of Internal Medicine at the University Hospital of Erlangen. All patients were intensively monitored for ADRs by a pharmacoepidemiological team. ADRs were evaluated for their offending drugs, probability, severity, preventability and classified by WHO-ART. During a 6-month period ADR-positive patients were matched to non-ADR patients applying diagnosis-related group categorization in order to measure the impact of ADRs on the duration and frequency of hospitalization.
Of 1000 admissions 424 patients had single admissions and 206 patients had recurrent readmissions (min 1, max 9). The prevalence of readmissions was 37% (n = 370). In 145 (23%) of 630 patients, 305 ADRs were observed. The ADR incidence was similar in first admissions and readmissions. ADRs were not found to predict further readmissions and lack of ADRs did not preclude readmissions. ADRs caused hospitalizations in 6.2% of first admissions and in 4.2% of readmissions. According to the Schumock algorithm 135 (44.3%) ADRs were found to be preventable. The occurrence and numbers of ADRs per admission were found to prolong hospitalization period significantly (r = 0.48 and 0.51, P < 0.001, n = 135). Of 9107 treatment days 20% were caused by in-house (1130 days) and community-acquired ADRs (669 days). In admissions and readmissions 11% (>973 days) of all treatment days were judged to be preventable.
Intensified drug monitoring supported by information technology in internal medicine is essential for early detecting and prevention of ADRs and saving hospital resources.
近期研究表明,近一半的住院患者在出院后6个月内再次入院。目前尚无关于药物不良反应(ADR)与内科再入院之间关系的数据。
本研究的主要目的是确定ADR是否可作为内科再次住院的预测指标,并评估ADR对住院费用的经济影响。
在埃尔朗根大学医院内科一部进行了一项基于队列的前瞻性药物流行病学调查,为期18个月。药物流行病学团队对所有患者进行了ADR的密切监测。对ADR的致病药物、可能性、严重程度、可预防性进行了评估,并根据世界卫生组织药物不良反应术语集(WHO-ART)进行分类。在6个月期间,采用诊断相关分组分类法将ADR阳性患者与非ADR患者进行匹配,以衡量ADR对住院时间和频率的影响。
在1000例入院患者中,424例患者为单次入院,206例患者为再次入院(最少1次,最多9次)。再入院率为37%(n = 370)。在630例患者中的145例(23%)中观察到305例ADR。首次入院和再次入院时的ADR发生率相似。未发现ADR可预测进一步的再入院,且无ADR也不能排除再入院。ADR导致6.2%的首次入院和4.2%的再次入院患者住院。根据舒莫克算法,发现135例(44.3%)ADR是可预防的。发现每次入院时ADR的发生情况和数量会显著延长住院时间(r = 0.48和0.51,P < 0.001,n = 135)。在9107个治疗日中,20%是由院内(1130天)和社区获得性ADR(669天)引起的。在入院和再入院中,所有治疗日的11%(>973天)被判定为可预防的。
内科中由信息技术支持的强化药物监测对于早期发现和预防ADR以及节省医院资源至关重要。